Daiichi Sankyo and MSD (Merck and Co.) have announced the dosing of the first subject in the Phase III IDeate-Lung02 clinical trial of ifinatamab deruxtecan (I-DXd) in people with relapsed small cell lung cancer (SCLC).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,